A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Trial Details

NCT ID

NCT07235293

Phase

PHASE2

Sponsor

Kahr Bio Australia Pty Ltd

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

DSP107 + Atezolizumab
Fruquintinib

Locations (sample)

Aurora, Colorado, United States|39.72943,-104.83192
Highlands Ranch, Colorado, United States|39.55388,-104.96943
Florida City, Florida, United States|25.44789,-80.47922
Durham, North Carolina, United States|35.99403,-78.89862
Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

Are ≥ 18 years of age with a life expectancy of \> 3 months.
Participants with histologically confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and …
Measurable disease per RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →